{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:01:55Z","timestamp":1793412115769,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health, Labour and Welfare Japan"},{"DOI":"10.13039\/501100007664","name":"Manpei Suzuki Diabetes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008644","name":"Japan Diabetes Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008644","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Most risk calculators that predict future cardiovascular disease (CVD) by baseline profiles are originally developed for primary prevention, but some studies applied the calculators to secondary prevention. We compared the impact of baseline profiles on the future CVD risk between patients with diabetes with and without a CVD history.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed a multicenter prospective cohort of 6338 Japanese patients with diabetes aged 40\u201374\u00a0years, including those with (<jats:italic>n<\/jats:italic>\u2009=\u2009634) and without a CVD history (<jats:italic>n<\/jats:italic>\u2009=\u20095704). The future risk of CVD was investigated using the competing risk model, with adjustment for non-cardiovascular mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the median follow-up of 6.9\u00a0years, 413 CVD events were observed. The 8-year cumulative incidence rates of CVD were 21.5% and 7.2% in patients with and without a CVD history, respectively. A higher systolic blood pressure and lower high-density lipoprotein cholesterol levels were independently associated with a future CVD risk in patients without a CVD history (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), whereas they were not associated in those with a CVD history. The <jats:italic>P<\/jats:italic> values for interaction were 0.040 and 0.005, respectively. The male sex, an older age, a longer duration of diabetes, higher hemoglobin A1c levels, and higher low-density lipoprotein cholesterol levels were common independent risk factors regardless of CVD history (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prognostic impact of metabolic profiles on CVD risk would not be identical between patients with and without a CVD history, suggesting that it might be inappropriate to apply CVD risk calculators developed for primary prevention to patients with a CVD history.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-021-01773-z","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T17:02:55Z","timestamp":1630342975000},"page":"57-65","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Different impacts of metabolic profiles on future risk of cardiovascular disease between diabetes with and without established cardiovascular disease: the Japan diabetes complication and its prevention prospective study 7 (JDCP study 7)"],"prefix":"10.1007","volume":"59","author":[{"given":"Mitsuyoshi","family":"Takahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-8320","authenticated-orcid":false,"given":"Naoto","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Hayashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimei","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Shimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihito","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A et al (2019) Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139:e56\u2013e528","journal-title":"Circulation"},{"key":"1773_CR2","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1093\/eurheartj\/ehi733","volume":"27","author":"J Leal","year":"2006","unstructured":"Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M (2006) Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 27:1610\u20131619","journal-title":"Eur Heart J"},{"key":"1773_CR3","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.06.022","volume":"26","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto K, Hanaoka S, Wu Y, Hasegawa T (2017) Comprehensive cost of illness of three major diseases in Japan. J Stroke Cerebrovasc Dis 26:1934\u20131940","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"C Emerging Risk Factors","year":"2010","unstructured":"Emerging Risk Factors C, Sarwar N, Gao P et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215\u20132222","journal-title":"Lancet"},{"key":"1773_CR5","doi-asserted-by":"crossref","unstructured":"Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study G (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101: 671-679","DOI":"10.1042\/cs1010671"},{"key":"1773_CR6","doi-asserted-by":"crossref","unstructured":"Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS, Atherosclerosis Risk in Communities Study I (2003) Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26: 2777-2784","DOI":"10.2337\/diacare.26.10.2777"},{"key":"1773_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580\u2013591","journal-title":"N Engl J Med"},{"key":"1773_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2019.0922","volume":"321","author":"S Balducci","year":"2019","unstructured":"Balducci S, D\u2019Errico V, Haxhi J et al (2019) Effect of a behavioral intervention strategy on sustained change in physical activity and sedentary behavior in patients with type 2 diabetes: the IDES_2 randomized clinical trial. JAMA 321:880\u2013890","journal-title":"JAMA"},{"key":"1773_CR9","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13280","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Zatti G, Baldi I et al (2018) Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study. Diabetes Obes Metab 20:1781\u20131786","journal-title":"Diabetes Obes Metab"},{"key":"1773_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.ajkd.2017.07.012","volume":"71","author":"YN Al Hamarneh","year":"2018","unstructured":"Al Hamarneh YN, Tsuyuki RT, Jones CA et al (2018) Effectiveness of pharmacist interventions on cardiovascular risk in patients with CKD: a subgroup analysis of the randomized controlled RxEACH trial. Am J Kidney Dis 71:42\u201351","journal-title":"Am J Kidney Dis"},{"key":"1773_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s13340-015-0223-1","volume":"6","author":"N Tajima","year":"2015","unstructured":"Tajima N, Nishimura R, Izumi K et al (2015) A large-scale, observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 2 diabetes: JDCP study 1. Diabetol Int 6:243\u2013251","journal-title":"Diabetol Int"},{"key":"1773_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s13340-015-0248-5","volume":"7","author":"R Nishimura","year":"2016","unstructured":"Nishimura R, Izumi K, Hayashino Y et al (2016) A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes: JDCP study 2. Diabetol Int 7:4\u201311","journal-title":"Diabetol Int"},{"key":"1773_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jdi.12550","volume":"8","author":"Y Hayashino","year":"2017","unstructured":"Hayashino Y, Izumi K, Okamura S et al (2017) Duration of diabetes and types of diabetes therapy in Japanese patients with type 2 diabetes: the Japan diabetes complication and its prevention prospective study 3 (JDCP study 3). J Diabetes Investig 8:243\u2013249","journal-title":"J Diabetes Investig"},{"key":"1773_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13340-018-0357-z","volume":"10","author":"R Kawasaki","year":"2019","unstructured":"Kawasaki R, Kitano S, Sato Y et al (2019) Factors associated with non-proliferative diabetic retinopathy in patients with type 1 and type 2 diabetes: the Japan diabetes complication and its prevention prospective study (JDCP study 4). Diabetol Int 10:3\u201311","journal-title":"Diabetol Int"},{"key":"1773_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdi.13116","volume":"11","author":"K Shikata","year":"2020","unstructured":"Shikata K, Kodera R, Utsunomiya K et al (2020) Prevalence of albuminuria and renal dysfunction, and related clinical factors in Japanese patients with diabetes: the Japan diabetes complication and its prevention prospective study 5. J Diabetes Investig 11:325\u2013332","journal-title":"J Diabetes Investig"},{"key":"1773_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s13340-015-0248-5","volume":"7","author":"R Nishimura","year":"2016","unstructured":"Nishimura R, Izumi K, Hayashino Y et al (2016) A large-scale observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 1 diabetes-JDCP study 2. Diabetol Int 7:4\u201311","journal-title":"Diabetol Int"},{"key":"1773_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T et al (2020) Japanese clinical practice guideline for diabetes 2019. Diabetol Int 11:165\u2013223","journal-title":"Diabetol Int"},{"key":"1773_CR18","unstructured":"Ministry of Education, Culture, Sports,, Science and Technology and Ministry of Health,, Labour and Welfare of Japan Ethical Guidelines for Epidemiologic Studies. https:\/\/www.mhlw.go.jp\/general\/seido\/kousei\/i-kenkyu\/ekigaku\/0504sisin.html. Accessed 29 June 2021 (in Japanese)"},{"key":"1773_CR19","doi-asserted-by":"crossref","unstructured":"Committee of the Japan diabetes society on the diagnostic criteria of diabetes M, Seino Y, Nanjo K, et al. (2010) Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 1: 212-228","DOI":"10.1111\/j.2040-1124.2010.00074.x"},{"key":"1773_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/jdi.12714","volume":"9","author":"H Yokoyama","year":"2017","unstructured":"Yokoyama H, Araki SI, Kawai K et al (2017) Current status of achieving blood pressure target and its clinical correlates in Japanese type 2 diabetes. J Diabetes Investig 9:594\u2013601","journal-title":"J Diabetes Investig"},{"key":"1773_CR21","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s00125-020-05337-8","volume":"64","author":"SJ Mould","year":"2021","unstructured":"Mould SJ, Soliman EZ, Bertoni AG, Bhave PD, Yeboah J, Singleton MJ (2021) Association of T-wave abnormalities with major cardiovascular events in diabetes: the ACCORD trial. Diabetologia 64:504\u2013511","journal-title":"Diabetologia"},{"key":"1773_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00125-009-1308-9","volume":"52","author":"HL Lutgers","year":"2009","unstructured":"Lutgers HL, Gerrits EG, Graaff R et al (2009) Skin autofluorescence provides additional information to the UK prospective diabetes study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52:789\u2013797","journal-title":"Diabetologia"},{"key":"1773_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2337\/dc16-1755","volume":"40","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Rigato M, Cappellari R, Bonora BM, Avogaro A (2017) Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes. Diabetes Care 40:125\u2013131","journal-title":"Diabetes Care"},{"key":"1773_CR24","doi-asserted-by":"crossref","unstructured":"UKPDS research group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703-713","DOI":"10.1136\/bmj.317.7160.703"},{"key":"1773_CR25","first-page":"1755","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension optimal treatment (HOT) randomised trial. HOT Study Group Lancet 351:1755\u20131762","journal-title":"HOT Study Group Lancet"},{"key":"1773_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/heartjnl-2012-301968","volume":"99","author":"S Bangalore","year":"2013","unstructured":"Bangalore S, Kumar S, Volodarskiy A, Messerli FH (2013) Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart 99:601\u2013613","journal-title":"Heart"},{"key":"1773_CR27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/01.hjh.0000226212.34055.86","volume":"24","author":"H Arima","year":"2006","unstructured":"Arima H, Chalmers J, Woodward M et al (2006) Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 24:1201\u20131208","journal-title":"J Hypertens"},{"key":"1773_CR28","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1161\/01.STR.0000094424.38761.56","volume":"34","author":"PM Rothwell","year":"2003","unstructured":"Rothwell PM, Howard SC, Spence JD, Carotid Endarterectomy Trialists C (2003) Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 34:2583\u20132590","journal-title":"Stroke"},{"key":"1773_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/jnnp-2013-305159","volume":"84","author":"H Yamauchi","year":"2013","unstructured":"Yamauchi H, Higashi T, Kagawa S, Kishibe Y, Takahashi M (2013) Impaired perfusion modifies the relationship between blood pressure and stroke risk in major cerebral artery disease. J Neurol Neurosurg Psychiatry 84:1226\u20131232","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1773_CR30","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.118.033348","volume":"138","author":"NK Itoga","year":"2018","unstructured":"Itoga NK, Tawfik DS, Lee CK, Maruyama S, Leeper NJ, Chang TI (2018) Association of blood pressure measurements with peripheral artery disease events. Circulation 138:1805\u20131814","journal-title":"Circulation"},{"key":"1773_CR31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.amjcard.2010.12.020","volume":"107","author":"M Banach","year":"2011","unstructured":"Banach M, Bhatia V, Feller MA et al (2011) Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol 107:1208\u20131214","journal-title":"Am J Cardiol"},{"key":"1773_CR32","doi-asserted-by":"crossref","unstructured":"Group AS, Cushman WC, Evans GW, et al. (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585","DOI":"10.1056\/NEJMoa1001286"},{"key":"1773_CR33","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/HJH.0b013e3283469976","volume":"29","author":"G Reboldi","year":"2011","unstructured":"Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253\u20131269","journal-title":"J Hypertens"},{"key":"1773_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61\u201368","journal-title":"JAMA"},{"key":"1773_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","volume":"55","author":"AA Bavry","year":"2010","unstructured":"Bavry AA, Anderson RD, Gong Y et al (2010) Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR\/Trandolapril STudy. Hypertension 55:48\u201353","journal-title":"Hypertension"},{"key":"1773_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D'Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117:743\u2013753","journal-title":"Circulation"},{"key":"1773_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572\u2013580","journal-title":"Lancet"},{"key":"1773_CR38","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M et al (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109\u20132122","journal-title":"N Engl J Med"},{"key":"1773_CR39","doi-asserted-by":"crossref","unstructured":"Streja L, Packard CJ, Shepherd J, Cobbe S, Ford I, Group W (2002) Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 90: 731-736","DOI":"10.1016\/S0002-9149(02)02599-7"},{"key":"1773_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5551\/jat.14.45","volume":"14","author":"T Teramoto","year":"2007","unstructured":"Teramoto T, Sasaki J, Ueshima H et al (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:45\u201350","journal-title":"J Atheroscler Thromb"},{"key":"1773_CR41","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2337\/dc06-2558","volume":"30","author":"A Avogaro","year":"2007","unstructured":"Avogaro A, Giorda C, Maggini M et al (2007) Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30:1241\u20131247","journal-title":"Diabetes Care"},{"key":"1773_CR42","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849\u20131861","journal-title":"Lancet"},{"key":"1773_CR43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S2213-8587(17)30327-3","volume":"5","author":"K Ueki","year":"2017","unstructured":"Ueki K, Sasako T, Okazaki Y et al (2017) Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5:951\u2013964","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1773_CR44","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1464-5491.2011.03347.x","volume":"28","author":"H Yokoyama","year":"2011","unstructured":"Yokoyama H, Matsushima M, Kawai K et al (2011) Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med 28:1221\u20131228","journal-title":"Diabet Med"},{"key":"1773_CR45","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.108.790048","volume":"118","author":"H Ueshima","year":"2008","unstructured":"Ueshima H, Sekikawa A, Miura K et al (2008) Cardiovascular disease and risk factors in Asia: a selected review. Circulation 118:2702\u20132709","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s00592-021-01802-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000}}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-021-01773-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-021-01773-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T07:12:19Z","timestamp":1642057939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-021-01773-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s00592-021-01773-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00592-021-01802-x","asserted-by":"object"}]},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00592-021-01802-x","URL":"https:\/\/doi.org\/10.1007\/s00592-021-01802-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mitsuyoshi Takahara received research support fees from The Japan Diabetes Society and received an endowed chair funded by AstraZeneca K.K., Keiseikai Medical Corporation, Mitsubishi Tanabe Pharma Corp., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd. Ono Pharmaceutical Co., Ltd., and Taisho Toyama Pharmaceutical Co. Ltd. Naoto Katakami is a staff member of the endowed chair established by funds from Kowa Co., Ltd., and has received research funds from MSD and lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Takeda Pharmaceutical Co., and Sanofi-Aventis, and Shionogi & Co. Yasuaki Hayashino reports personal fees from Boehringer Ingelheim, Merck & Co., Inc., Kowa Pharmaceuticals, Inc., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company, Ltd., and Teijin Pharma Limited, outside the submitted work. Rimei Nishimura has received honoraria from Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd, Eli Lilly Japan K.K., Kissei Pharmaceutical Co. Ltd, Medtronic Japan Co. Ltd, MSD, Novartis Pharma K.K., Novo Nordisk Pharma Ltd, Sanofi K.K., Sumitomo Dainippon Pharma Co. Ltd., and Takeda Pharmaceutical Co. Ltd. He has also received a grant from the Japan Diabetes Foundation and Nippon Boehringer Ingelheim Co. Ltd. Hitoshi Shimano received research funds from and endowed chair or speaker fees from Kowa Company Ltd., Astellas Pharma Inc. and MSD. Naoko Tajima has received honoraria from Nippon Boehringer Ingelheim Co. Ltd and Takeda Pharmaceutical Co. Ltd. Yoshimitsu Yamasaki received research fees from AstraZeneca K.K., Taisho Toyama Pharmaceutical Co. Ltd., Eli Lilly, and Bayer Yakuhin, Ltd. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the JDS Ethics Review Committee for Scientific Surveys and Studies and the Ethics Committee of each participating institution (or an ad hoc ethics committee convened at the request of the principal investigator if the required review process could not be put in place at any of the participating institutions).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard Statement"}}]}}